Scientists have discovered what triggers one of the most deadly types of breast cancer, raising hopes of new treatments for it. They have pinpointed a gene that drives triple-negative breast cancer – an especially fast-growing and hard-to-treat form of the disease. It accounts for up to one in five cases of breast cancer and is particularly likely to strike women when they are still in their 20s and 30s. Scroll down for video . Scientists have discovered a gene which drives a fast-growing, aggressive form of breast cancer . Breast cancer drugs from the gold-standard treatment tamoxifen to ‘wonder drug’ Herceptin are useless against it and it has a worse prognosis than other forms of the disease. The breakthrough, spearheaded by researchers from the Wellcome Trust Sanger Institute near Cambridge, brings hope of new treatments. The study of breast cancers from almost 3,000 women revealed a gene called BCL11A to be particularly active in triple-negative tumours. Women with the gene had cancer that was more advanced. And extra copies of the gene cut a woman’s survival chances, the journal Nature Communications reports. Experiments on mice confirmed the gene’s importance. For instance, animals destined to develop breast cancer remained free of the disease when the gene was inactivated. And ‘turning down’ the gene in cells made them less cancerous. Triple-negative breast cancer tends to be more aggressive than other types of breast cancer. Studies have shown it is more likely to spread beyond the breast and more likely to recur after treatment. These risks appear to be greatest in the first few years after treatment. The breakthrough paves the way for new treatments for this type of the disease, which is notoriously difficult to treat. Breast cancer cells are pictured . Researcher Professor Carlos Caldas said: ‘This exciting result identifies a novel breast cancer gene in some of the more difficult-to-treat cases.’ Dr Emma Smith, of Cancer Research UK, said: ‘Figuring out the genes that play a role in triple negative breast cancer could lead to new ways to tackle the disease. 'This study is a promising step forward. 'But these results are from cells grown in the lab and studies in mice, so they’re still at an early stage. ‘The next steps will be finding out if the gene plays the same role in causing breast cancer in women, and whether drugs can be developed to target the faulty molecules. ‘Triple-negative breast cancer can be challenging to treat, so research into the biology of the disease is vital to help scientists come up with new treatments.’ This type of cancer tends to be more aggressive than other types of breast cancer. Studies have shown triple-negative breast cancer is more likely to spread beyond the breast and more likely to recur after treatment. These risks appear to be greatest in the first few years after treatment. Anyone can get triple-negative breast cancer, but researchers have found it is more likely to affect: . Younger people: Triple-negative breast cancer is more likely to occur before age 40 or 50, versus age 60 or older, which is more typical for other breast cancer types. African-American and Hispanic women: Triple-negative breast cancer most commonly affects African-American women, followed by Hispanic women. One study found that black women were 3 times more likely to develop triple-negative breast cancer than white women. People with a BRCA1 mutation: When people with an inherited BRCA1 mutation develop breast cancer, especially before age 50, it is usually found to be triple-negative. Like other forms of breast cancer, triple-negative breast cancer is treated with surgery, radiation therapy, and/or chemotherapy . Source: Breastcancer.org .
Triple-negative breast cancer is fast-growing and hard to treat .
Is particularly likely to strike women when they are still in their 20s and 30s .
Now scientists have pinpointed a gene that drives this type of cancer .
Gene called BCL11A is particularly active in triple-negative tumours .
Scientists have discovered what triggers one of the most deadly types of breast cancer, raising hopes of new treatments for it. They have pinpointed a gene that drives triple-negative breast cancer – an especially fast-growing and hard-to-treat form of the disease. It accounts for up to one in five cases of breast cancer and is particularly likely to strike women when they are still in their 20s and 30s. Scroll down for video . Scientists have discovered a gene which drives a fast-growing, aggressive form of breast cancer . Breast cancer drugs from the gold-standard treatment tamoxifen to ‘wonder drug’ Herceptin are useless against it and it has a worse prognosis than other forms of the disease. The breakthrough, spearheaded by researchers from the Wellcome Trust Sanger Institute near Cambridge, brings hope of new treatments. The study of breast cancers from almost 3,000 women revealed a gene called BCL11A to be particularly active in triple-negative tumours. Women with the gene had cancer that was more advanced. And extra copies of the gene cut a woman’s survival chances, the journal Nature Communications reports. Experiments on mice confirmed the gene’s importance. For instance, animals destined to develop breast cancer remained free of the disease when the gene was inactivated. And ‘turning down’ the gene in cells made them less cancerous. Triple-negative breast cancer tends to be more aggressive than other types of breast cancer. Studies have shown it is more likely to spread beyond the breast and more likely to recur after treatment. These risks appear to be greatest in the first few years after treatment. The breakthrough paves the way for new treatments for this type of the disease, which is notoriously difficult to treat. Breast cancer cells are pictured . Researcher Professor Carlos Caldas said: ‘This exciting result identifies a novel breast cancer gene in some of the more difficult-to-treat cases.’ Dr Emma Smith, of Cancer Research UK, said: ‘Figuring out the genes that play a role in triple negative breast cancer could lead to new ways to tackle the disease. 'This study is a promising step forward. 'But these results are from cells grown in the lab and studies in mice, so they’re still at an early stage. ‘The next steps will be finding out if the gene plays the same role in causing breast cancer in women, and whether drugs can be developed to target the faulty molecules. ‘Triple-negative breast cancer can be challenging to treat, so research into the biology of the disease is vital to help scientists come up with new treatments.’ This type of cancer tends to be more aggressive than other types of breast cancer. Studies have shown triple-negative breast cancer is more likely to spread beyond the breast and more likely to recur after treatment. These risks appear to be greatest in the first few years after treatment. Anyone can get triple-negative breast cancer, but researchers have found it is more likely to affect: . Younger people: Triple-negative breast cancer is more likely to occur before age 40 or 50, versus age 60 or older, which is more typical for other breast cancer types. African-American and Hispanic women: Triple-negative breast cancer most commonly affects African-American women, followed by Hispanic women. One study found that black women were 3 times more likely to develop triple-negative breast cancer than white women. People with a BRCA1 mutation: When people with an inherited BRCA1 mutation develop breast cancer, especially before age 50, it is usually found to be triple-negative. Like other forms of breast cancer, triple-negative breast cancer is treated with surgery, radiation therapy, and/or chemotherapy . Source: Breastcancer.org .
pinpointed a gene that drives triple-negative is particularly likely to strike women when they are still in their 20s and 30s. Scroll down for to be particularly active in triple-negative for new treatments for this type of the disease, people: Triple-negative breast cancer is more